# Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.

> **NCT05282030** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 22 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** tolebrutinib

## Key facts

- **NCT ID:** NCT05282030
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-10
- **Primary completion:** 2022-08-02
- **Final completion:** 2022-08-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05282030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05282030, "Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05282030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*